GlassScriptPhysician profile
Emily Fechner
NPI 1669839304
$18,445.50
in general payments reported to CMS, 2019-2025
74 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,065 · 2022: $3,635 · 2023: $4,486 · 2024: $4,807 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Long Term Medical Supply Or Device Loan: $1,280 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,344.95 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $120.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,216.50 | 2021-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $1,302.80 | 2021-2025 | Darzalex, Talvey, Erleada |
| Pfizer INC. | $860.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $797.06 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $763.95 | 2021-2025 | Opdualag, Opdivo |
| Amgen INC. | $752.87 | 2021-2024 | Vectibix, Prolia, Lumakras |
| Merck Sharp & Dohme LLC | $717.60 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $657.15 | 2021-2025 | Jakafi, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $614.20 | 2021-2025 | Alunbrig, Fruzaqla, Vpriv |
| Abbvie INC. | $612.73 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $538.29 | 2021-2025 | Provenge |
| Genentech USA, INC. | $530.72 | 2022-2025 | Polivy, Columvi, Lunsumio |
| Lilly USA, LLC | $450.09 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $436.22 | 2021-2023 | Adcetris |
| Celgene Corporation | $434.46 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $427.03 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $368.83 | 2021-2024 | Libtayo |
| Daiichi Sankyo INC. | $328.09 | 2021-2025 | Injectafer, Enhertu, Vanflyta |
| Tersera Therapeutics LLC | $301.72 | 2022-2024 | Quzyttir, Xermelo |
| Beigene USA, INC. | $291.25 | 2021-2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $260.87 | 2021-2025 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $243.95 | 2021-2023 | Imbruvica |
| Jazz Pharmaceuticals INC. | $235.03 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $173.53 | 2022-2025 | |
| Blue Earth Diagnostics | $161.08 | 2021-2024 | |
| Mirati Therapeutics, INC. | $153.33 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $149.04 | 2021-2025 | Ojjaara, Shingrix |
| Pharmacosmos Therapeutics INC. | $142.62 | 2022-2024 | Cosela, Monoferric |
| Emd Serono, INC. | $133.77 | 2022-2024 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $129.70 | 2021-2024 | |
| Blueprint Medicines Corporation | $111.21 | 2022-2024 | Ayvakit |
| Sobi, INC | $109.53 | 2022-2025 | |
| Astellas Pharma US INC | $107.48 | 2021-2024 | Padcev |
| Morphosys, US INC. | $107.41 | 2022-2023 | Monjuvi |
| Gilead Sciences, INC. | $107.41 | 2021-2023 | Trodelvy |
| Agios Pharmaceuticals, INC. | $106.04 | 2023-2025 | Pyrukynd |
| Eisai INC. | $99.75 | 2021-2024 | |
| Deciphera Pharmaceuticals INC. | $97.59 | 2022-2025 | Qinlock, Romvimza |
| Karyopharm Therapeutics INC. | $80.92 | 2021-2022 | |
| Kite Pharma, INC. | $76.17 | 2021-2025 | Yescarta |
| G1 Therapeutics, INC. | $74.61 | 2022-2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $73.91 | 2022-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $68.71 | 2021-2025 | Givlaari |
| Pharmaessentia USA Corporation | $67.28 | 2023-2025 | Besremi |
| Eusa Pharma (US) LLC | $59.89 | 2021-2022 | |
| Geron Corporation | $58.42 | 2025 | Rytelo |
| Novocure INC. | $58.19 | 2021-2025 | Optune Lua (Novottf-200t) |
| Aveo Pharmaceuticals, INC. | $57.18 | 2024-2025 | |
| Array Biopharma INC | $53.40 | 2022-2025 | Lorbrena |
| Adc Therapeutics America, INC. | $50.46 | 2024-2025 | |
| Cti Biopharma Corp. | $47.60 | 2023 | Vonjo |
| Novo Nordisk INC | $47.13 | 2021-2024 | |
| Intera Oncology, INC | $42.63 | 2025 | Intera |
| Tempus Ai, INC | $39.69 | 2024-2025 | Xt Cdx |
| Amag Pharmaceuticals, INC. | $37.55 | 2021 | |
| Acrotech Biopharma INC. | $36.13 | 2023-2025 | Beleodaq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.60 | 2025 | |
| Menarini Silicon Biosystems, INC. | $29.80 | 2022-2023 | Cellsearch |
| Stemline Therapeutics INC. | $28.48 | 2025 | Orserdu |
| Kyowa Kirin, INC. | $24.01 | 2025 | |
| Taiho Oncology, INC. | $23.94 | 2025 | |
| Exelixis INC. | $22.20 | 2024 | Cabometyx |
| Myriad Genetic Laboratories, INC. | $21.83 | 2022 | |
| Immunogen, INC. | $21.01 | 2023 | Elahere |
| Coherus Oncology, INC. | $20.15 | 2021 | |
| Dova Pharmaceuticals | $20.11 | 2021 | |
| Melinta Therapeutics, LLC | $20.10 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Janssen Pharmaceuticals, INC | $19.51 | 2023 | Xarelto |
| Ipsen Biopharmaceuticals, INC | $19.24 | 2025 | Onivyde |
| Puma Biotechnology, INC. | $18.88 | 2021 | |
| Syndax Pharmaceuticals, INC. | $18.73 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $15.99 | 2023 | Akynzeo |
| Springworks Therapeutics, INC. | $14.78 | 2024 | Ogsiveo |
| Recordati_rare_diseases_inc. | $14.39 | 2025 | Enjaymo |
Drugs and devices associated with these payments
Kisqali $1,668Provenge $473Imbruvica $431Darzalex $421Keytruda $372Venclexta $326Calquence $301Opdualag $281Talvey $258Scemblix $253Verzenio $243Clonoseq $242Polivy $240Epkinly $229Quzyttir $210Jakafi $208Zepzelca $207Columvi $196Lunsumio $193Adcetris $187Pluvicto $183Libtayo $179Erleada $178Piqray $175Monjuvi $172Brukinsa $171Lynparza $171Pomalyst $162Ibrance $162Krazati $153Enhertu $150Welireg $148Elrexfio $146Rybrevant $144Inlyta $143Akeega $128Tecvayli $126Alunbrig $124Lutathera $115Opdivo $114Xtandi $114Vonjo $112Pyrukynd $106Padcev $105Ojjaara $104Vectibix $102Tukysa $102Talzenna $101Fruzaqla $99.43Balversa $98.67Imfinzi $96.77Bosulif $94.66Ayvakit $93.50Cosela $93.43Promacta $89.44Prolia $87.76Lumakras $84.46Tibsovo $81.09Nplate $79.09Injectafer $76.68Lorbrena $76.60Enjaymo $75.51Fabhalta $75.05Jaypirca $71.63Elahere $71.32Qinlock $71.31Posluma $68.11Besremi $67.28Stivarga $67.25Vitrakvi $67.25Tasigna $65.22Cablivi $61.12Bavencio $59.68Rytelo $58.42Fotivda $57.18Cerezyme $56.45Evenity $56.22Besponsa $53.72Oxbryta $51.87Lenvima $50.34Phesgo $49.79Vpriv $46.39Comirnaty $45.17Reblozyl $44.98Iclusig $44.02Intera $42.63Tecentriq $40.28Alecensa $40.28Gavreto $40.28Rozlytrek $40.28Monoferric $37.13Beleodaq $36.13Vanflyta $33.90Xermelo $33.28Carvykti $32.21Akynzeo $31.98Mekinist $31.10Yescarta $30.54Xalkori $29.80Shingrix $28.98
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Fechner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.